2021
Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeath
2020
Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis
Losina E, Silva GS, Smith KC, Collins JE, Hunter DJ, Shrestha S, Messier SP, Yelin EH, Suter LG, Paltiel AD, Katz JN. Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. Arthritis Care & Research 2020, 72: 1349-1357. PMID: 31350803, PMCID: PMC6982563, DOI: 10.1002/acr.24035.Peer-Reviewed Original ResearchConceptsKnee osteoarthritisCases of cancerPhysical activityPhysical inactivityUS populationCardiovascular diseasePA levelsQuality-adjusted life year (QALY) lossBlack Hispanic womenHealth benefitsInsufficient physical activityQuality-adjusted life yearsLife-year lossHigher PA levelsRace/ethnicityDiabetes mellitusHispanic womenOsteoarthritisQALY lossLife yearsOsteoarthritis InitiativeLoss burdenDisease controlImproved healthActivity levels
2017
A Flow-Based Model of the HIV Care Continuum in the United States
Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Tang T, Hall HI, Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 548-553. PMID: 28471841, PMCID: PMC5533168, DOI: 10.1097/qai.0000000000001429.Peer-Reviewed Original ResearchConceptsViral suppressionAntiretroviral therapyHIV careNorth American AIDS Cohort CollaborationProportion of HIVHIV care continuumCohort CollaborationHIV diagnosisAntiretroviral treatmentVirological dataCare continuumFlow of patientsDisease controlPatientsCareAverage timeHIVTherapyLaboratory resultsMonthsSuppressionYearsDiagnosisIndividualsPrevention
2011
Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal Of General Internal Medicine 2011, 26: 661-667. PMID: 21286837, PMCID: PMC3101973, DOI: 10.1007/s11606-011-1637-5.Peer-Reviewed Original ResearchConceptsPotential survival gainsSurvival gainHIV testingDiagnosis rateAnnual HIV incidenceProportion of HIVUndiagnosed HIV prevalenceAnnual HIV diagnosis ratesHIV diagnosis ratesHIV incidenceHIV prevalenceEarly diagnosisHIVDisease controlLYGSurveillance dataAdult personsConsentConsent methodsPersonsPatientsConsent lawsBackgroundAlthoughDesignWeObjectiveTo
2010
Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV Screening in the United States: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. Value In Health 2010, 13: 893-902. PMID: 20950323, PMCID: PMC2999642, DOI: 10.1111/j.1524-4733.2010.00763.x.Peer-Reviewed Original ResearchConceptsHIV screeningEarly treatment goalsNew HIV casesFrequency of screeningBudget impact analysisTotal budget increasesHIV careAnnual incidenceHIV casesHIV prevalenceCDC estimatesUS CentersTreatment goalsBudget impactTreatment programDisease controlHIVTest characteristicsTreatment costsFinancial burdenCareScreeningSmall proportionProgram savingsFund care
2007
Cost-Effectiveness of HIV Testing and Treatment in the United States
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-Effectiveness of HIV Testing and Treatment in the United States. Clinical Infectious Diseases 2007, 45: s248-s254. PMID: 18190295, PMCID: PMC2365915, DOI: 10.1086/522546.Peer-Reviewed Original ResearchConceptsHIV testingVoluntary human immunodeficiency virus (HIV) testingHuman immunodeficiency virus (HIV) testingRoutine HIV testingVoluntary HIV testingLower cost-effectiveness ratioCost-effectiveness ratioCost-effectiveness studiesHealth care settingsPublic health importanceHealth care interventionsCost-effectiveness analysisImmunodeficiency syndromeRisk factorsCare interventionsUS CentersCare settingsVirus testingHealth effectivenessHealth importanceDisease controlRecent evidenceHIVNew guidelinesUnited States
2005
Routine human immunodeficiency virus testing: An economic evaluation of current guidelines
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. The American Journal Of Medicine 2005, 118: 292-300. PMID: 15745728, DOI: 10.1016/j.amjmed.2004.07.055.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHIV prevalenceCurrent guidelinesHuman immunodeficiency virus (HIV) counselingMean quality-adjusted life expectancyHIV Screening ProgramQuality-adjusted life expectancyLife-sustaining careOverall participation rateCost-effectiveness analysisUndiagnosed infectionHIV screeningHIV counselingClinical effectsReferral guidelinesPrevention guidelinesInfected patientsScreening programDisease controlPrevalenceU.S. hospitalsScreening thresholdLife expectancyHIVPatients